Drug Profile
Herpes simplex vaccine - CEL-SCI
Latest Information Update: 03 May 2007
Price :
$50
*
At a glance
- Originator CEL-SCI Corporation
- Developer CEL-SCI Corporation; Northeastern Ohio Universities College of Medicine
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Herpes simplex virus infections
Most Recent Events
- 28 Mar 2002 Data from a study have been added to the Viral Infections pharmacodynamics field
- 24 Oct 2000 CEL-SCI has received a phase II SBIR grant of approximately $US764 000 from NIAID to support development of its herpes simplex vaccine
- 03 May 2000 A preclinical study has been added to the Viral Infections pharmacodynamics section